BiotiQuest® Gut Health & Probiotics Blog with Martha Carlin

BioFlux™ Model validation study (Sugar Shift)

Martha Carlin | Mar 10, 2022 | 1 minutes read

We take the research side of product development very seriously. Using our proprietary BioFlux™ system to model interactions between microbes in a system, we are able to better predict the ideal microbe strains to combine in formulas for usefulness, impact, and overall viability.

Our in silico modeling produces actionable results allowing BiotiQuest to be more efficient, rapid prototype potential blends and optimize existing products.

The BioFlux™ probiotic modeling system is so powerful because:

  • It uses one of the world's largest whole stool microbiome sample banks. With applications in metabolomics, metagenomics, proteomics and strain isolation.

  • Our strain-bank of over 1,500 unique organisms. This allows us to maximize taxonomic and functional diversity for optimal capabilities in formula development and biotechnological applications.

  • Metagenomic database Our metagenomic data sets provide taxonomic and functional characteristics of multiple cohorts, as well as whole genomic information for individual strains including antibiotic resistance and virulence. 

We tested Sugar Shift to validate our assumptions

This document summarizes the results with the use of BiotiQuest™ Sugar Shift in an in vitro and in a human subjects’ study to validate the predictions of the BioFlux™ Model in terms of increased mannitol, butyrate, siderophore production and glycolytic activity.


Click HERE to view the case study in its entirety. 



With gratitude,


Martha Carlin, is a “Citizen Scientist”, systems thinker, wife of Parkinson’s warrior, John Carlin, and founder of The BioCollective , a microbiome company expanding the reach of science and BiotiQuest, the first of it’s kind probiotic line. Since John’s diagnosis in 2002, Martha began learning the science of agriculture, nutrition, environment, infectious disease, Parkinson’s pathology and much more. In 2014, when the first research was published showing a connection between the gut bacteria and the two phenotypes of Parkinson’s, Martha quit her former career as a business turnaround expert and founded The BioCollective to accelerate the discovery of the impact of gut health on all human disease. Martha was a speaker at the White House 2016 Microbiome Initiative launch, challenging the scientific community to “think in a broader context”. Her systems thinking background and experience has led to collaborations across the scientific spectrum from neuroscience to engineering to infectious disease. She is a respected out of the box problem solver in the microbiome field and brings a unique perspective to helping others understand the connections from the soil to the food to our guts and our brains.

The Martha's Favorite Posts